因美纳推出"十亿细胞图谱"，加速人工智能与药物发现

美通社01-14

该图谱将以空前规模用于遗传靶点验证与 AI 模型训练圣迭戈2026年1月14日 /美通社/ -- 2026年1月13日，因美纳公司（纳斯达克股票代码：ILMN）推出全球最大的、覆盖全基因组的遗传扰动数据集，旨在通过人工智能加速整个制药生态系统的药物发现进程。因美纳 "十亿细胞图谱"（Illumina Billion Cell Atlas）是其在三年内构建"五十亿细胞图谱"计划的首批成果，将成为...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2603664987?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2026-01-14 12:13","share_image_url":"https://static.laohu8.com/7d5258e5fa9d58069a293859983c0a71","id":"2603664987","market":"us","top_or_hot":-1,"title":"因美纳推出\"十亿细胞图谱\"，加速人工智能与药物发现","media":"美通社","content":"<div>\n<p>该图谱将以空前规模用于遗传靶点验证与 AI 模型训练 圣迭戈2026年1月14日 /美通社/ -- 2026年1月13日，因美纳公司（纳斯达克股票代码：ILMN）推出全球最大的、覆盖全基因组的遗传扰动数据集，旨在通过人工智能加速整个制药生态系统的药物发现进程。因美纳 \"十亿细胞图谱\"（Illumina Billion Cell Atlas）是其在三年内构建\"五十亿细胞图谱\"计划的首批成果，将成为...</p>\n\n<a href=\"http://wwwold.prnasia.com/story/archive/4863066_ZH63066_1\">网页链接</a>\n\n</div>\n","source":"prnasia","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>因美纳推出\"十亿细胞图谱\"，加速人工智能与药物发现</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n因美纳推出\"十亿细胞图谱\"，加速人工智能与药物发现\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-01-14 12:13 北京时间&nbsp;&nbsp;&nbsp;<a href=http://wwwold.prnasia.com/story/archive/4863066_ZH63066_1><strong>美通社</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>该图谱将以空前规模用于遗传靶点验证与 AI 模型训练 圣迭戈2026年1月14日 /美通社/ -- 2026年1月13日，因美纳公司（纳斯达克股票代码：ILMN）推出全球最大的、覆盖全基因组的遗传扰动数据集，旨在通过人工智能加速整个制药生态系统的药物发现进程。因美纳 \"十亿细胞图谱\"（Illumina Billion Cell Atlas）是其在三年内构建\"五十亿细胞图谱\"计划的首批成果，将成为...</p>\n\n<a href=\"http://wwwold.prnasia.com/story/archive/4863066_ZH63066_1\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU2089984988.USD","symbol_name":"MANULIFE GF HEALTHCARE \"AA\" (USD) ACC","start_time":0,"source_url":"http://wwwold.prnasia.com/story/archive/4863066_ZH63066_1","article_id":"2603664987","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2603664987","pubTimestamp":1768363980,"columns":[],"sourceInfo":{"source_id":"prnasia","name":"美通社"},"weMediaInfo":null,"summary":"\" BioInsight 团队如何构建因美纳首个数据产品  因美纳推出“十亿细胞图谱”，加速人工智能与药物发现  \"十亿细胞图谱\"是因美纳新业务部门BioInsight推出的首个数据产品。通过推出因美纳\"十亿细胞图谱\"，并开发面向特定疾病的综合基因扰动数据集，结合先进的AI算法，因美纳正在推动新一代细胞建模的进展。此次\"十亿细胞图谱\"建立在因美纳于2025年2月宣布的合作倡议之上，其最终目标是创建一个\"五十亿单细胞图谱\"。","collect":0,"end_time":0,"defaultTopTitle":"prnasia.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"LU2089984988.USD":"MANULIFE GF HEALTHCARE \"AA\" (USD) ACC","SG9999014575.USD":"UOB UNITED INCOME FOCUS TRUST FUND (USDHDG) INC","LU1037948541.HKD":"AB LOW VOLATILITY EQUITY PORTFOLIO \"A\" (HKD) ACC","LU0985320562.USD":"NORDEA 1 GLOBAL STARS EQUITY \"BP\" (USD) ACC","LU0238689110.USD":"贝莱德环球动力股票基金","LU1941712264.USD":"ALLIANZ PET AND ANIMAL WELLBEING \"A\" (USD) INC","LU1934455194.USD":"AB SICAV I LOW VOLATILITY TOTAL RETURN EQUITY PORT \"A\" (USD) ACC","LU1116320737.USD":"BGF SYSTEMATIC GLOBAL ENHANCED EQUITY YIELD \"A6\" (USD) INC","IE00BJJMRZ35.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (SGDHDG) ACC","LU2461242641.AUD":"WELLINGTON US QUALITY GROWTH \"A\" (AUDHDG) ACC","LU1162221912.USD":"FRANKLIN INCOME \"A\" (USD) ACC","IE00B4R5TH58.HKD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"A2\" (HKD) ACC","IE00B1BXHZ80.USD":"Legg Mason ClearBridge - US Appreciation A Acc USD","LU1116320901.HKD":"BGF SYSTEMATIC GLOBAL ENHANCED EQUITY YIELD \"A6\" (HKD) INC","LU0203347892.USD":"SCHRODER ISF QEP GLOBAL ACTIVE VALLUE \"A\" (USD)  INC AV","ILMN":"Illumina","SG9999014559.SGD":"United Income Focus Trust Dis SGD","LU1035773651.USD":"AB SICAV I - GLOBAL VALUE PORTFOLIO \"AD\" (USD) INC","LU2324357040.USD":"HSBC GIF GLOBAL EQUITY SUSTAINABLE HEALTHCARE \"AC\" (USD) ACC","LU0203345920.USD":"SCHRODER ISF QEP GLB ACT. VL \"A\" (USD) ACC","BK4543":"AI","LU1941712348.USD":"ALLIANZ PET AND ANIMAL WELLBEING \"AT\" (USD) ACC","LU1585245621.USD":"EASTSPRING INV GLOBAL LOW VOLATILITY EQUITY FUND \"A\" (USD) ACC B","LU0098860793.USD":"FRANKLIN INCOME \"A\" INC","LU0211331839.USD":"FRANKLIN MUTUAL GLB DISCOVERY \"A\" (USD) ACC","SG9999014567.USD":"UOB UNITED INCOME FOCUS TRUST FUND (USD) ACC","BK4534":"瑞士信贷持仓","LU2023250843.SGD":"Allianz Thematica Cl AT Acc H2-SGD","BK4533":"AQR资本管理(全球第二大对冲基金)","SG9999015358.SGD":"United Income Focus Trust Dis SGD-H","LU0320765646.SGD":"FTIF - Franklin Income A MDIS SGD-H1","LU2112291526.USD":"BGF WORLD HEALTHSCIENCE \"A4\" (USD) INC","BK4516":"特朗普概念","BK4535":"淡马锡持仓","IE00BFTCPJ56.SGD":"Janus Henderson Global Life Sciences A Acc SGD","LU0208291251.USD":"FRANKLIN MUTUAL U.S. VALUE \"A\" (USD) INC","LU2125154778.USD":"ALLSPRING GLOBAL EQUITY ENHANCED INCOME \"A\" (USD) INC","LU0130102774.USD":"Natixis Harris Associates US Equity RA USD","LU0130517989.USD":"HARRIS ASSOCIATES US VALUE EQUITY \"R\" INC","BK4548":"巴美列捷福持仓","LU0861579265.USD":"联博低波幅策略股票基金A","LU0234572021.USD":"高盛美国核心股票组合Acc","SGXZ57979304.SGD":"United Global Healthcare A Acc SGD-H","IE000M9KFDE8.USD":"NEUBERGER BERMAN US LARGE CAP VALUE \"A\" (USD) ACC","LU0477156953.USD":"HARRIS ASSOCIATES US VALUE EQUITY \"RE\" (USD) ACC","LU0965509010.AUD":"AB LOW VOLATILITY EQUITY PORTFOLIO \"AD\" (AUDHDG) INC","BK4023":"应用软件","SG9999001176.USD":"United Global Healthcare Acc USD","LU0006306889.USD":"SCHRODER ISF US LARGE CAP \"A\" (USD) INC AV","LU1057294990.SGD":"Blackrock World Healthscience A2 SGD-H","LU1571399168.USD":"ALLSPRING GLOBAL LONG/SHORT EQUITY \"IP\" (USD) ACC","AI":"C3.ai, Inc.","BK4585":"ETF&股票定投概念","IE00BLSP4239.USD":"Legg Mason ClearBridge - Tactical Dividend Income A Mdis USD Plus","LU0965509283.SGD":"AB LOW VOLATILITY EQUITY PORTFOLIO \"AD\" (SGDHDG) INC","IE0002141913.USD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (USD) ACC","BK4587":"ChatGPT概念","LU2106854487.HKD":"ALLIANZ THEMATICA \"AMG\" (HKD) INC","LU1061106388.HKD":"BGF WORLD HEALTHSCIENCE \"A2\" (HKDHDG) ACC","IE00BN8TJ469.HKD":"FTGF CLEARBRIDGE TACTICAL DIVIDEND INCOME \"A\" (HKD) INC","BK4559":"巴菲特持仓","LU0965509101.SGD":"AB LOW VOLATILITY EQUITY PORTFOLIO \"A\" (SGDHDG) ACC","BK4550":"红杉资本持仓","BK4588":"碎股","LU0106261372.USD":"SCHRODER ISF US LARGE CAP \"A\" ACC","IE00BBT3K403.USD":"LEGG MASON CLEARBRIDGE TACTICAL DIVIDEND INCOME \"A(USD) ACC","SG9999013999.USD":"UOB UNITED GLOBAL HEALTHCARE FUND (USDHDG) INC","LU0122379950.USD":"贝莱德世界健康科学A2","LU1983299246.USD":"SCHRODER ISF HEALTHCARE INNOVATION \"A\" (USD) ACC","SG9999001176.SGD":"UOB UNITED GLOBAL HEALTHCARE \"SGD\" (ACC)","IE00BSNM7G36.USD":"NEUBERGER BERMAN SYSTEMATIC GLOBAL SUSTAINABLE VALUE \"A\" (USD) ACC","BK4551":"寇图资本持仓","LU1291159041.SGD":"CPR Invest - Global Silver Age A2 Acc SGD-H","IE0009355771.USD":"骏利亨德森环球生命科技A Acc","LU0320765489.SGD":"FTIF - Franklin Mutual US Value A Acc SGD","LU1066051225.USD":"HSBC GIF GLOBAL EQUITY VOLATILITY FOCUSED \"AC\" (USD) ACC","LU0266013472.USD":"AXA WF - Framlington Longevity Economy A Cap USD","LU1430594728.SGD":"Eastspring Investments - Global Low Volatility Equity AS SGD","IE00B2B36J28.USD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I1\" (USD) INC","LU1069347547.HKD":"AB SICAV I - GLOBAL VALUE PORTFOLIO \"AD\" (HKD) INC","IE00BLSP4452.SGD":"Legg Mason ClearBridge - Tactical Dividend Income A Mdis SGD-H Plus","LU1917777945.USD":"安联专题基金Cl AT Acc","SG9999002232.USD":"Allianz Global High Payout USD","LU1699723380.USD":"ALLSPRING GLOBAL LONG/SHORT EQUITY \"AP\" (USD) ACC","SG9999002224.SGD":"Allianz Global High Payout SGD","SG9999015341.SGD":"United Income Focus Trust Acc SGD-H","LU0265550946.USD":"BGF SYSTEMATIC GLOBAL ENHANCED EQUITY YIELD \"A5\" (USD) INC","BK4528":"SaaS概念","LU1934455863.HKD":"AB SICAV I LOW VOLATILITY TOTAL RETURN EQUITY PORT \"A\" (HKD) ACC","LU2361044949.HKD":"WELLINGTON US QUALITY GROWTH \"A\" (HKD) ACC","LU1066051811.HKD":"HSBC GIF GLOBAL EQUITY VOLATILITY FOCUSED \"AM2\" (HKD) INC","LU1023059063.AUD":"BGF WORLD HEALTHSCIENCE \"A2\" (AUDHDG) ACC","SG9999014542.SGD":"United Income Focus Trust Acc SGD","LU2360032135.SGD":"ALLSPRING GLOBAL EQUITY ENHANCED INCOME \"A\" (SGDHDG) INC","LU2361044865.SGD":"WELLINGTON US QUALITY GROWTH \"A\" (SGDHDG) ACC","LU1201861249.SGD":"Natixis Harris Associates US Equity PA SGD-H","LU0070302665.USD":"FRANKLIN MUTUAL U.S. VALUE \"A\" (USD) ACC","LU0980610538.SGD":"Natixis Harris Associates US Equity RA SGD-H","LU1929549753.HKD":"FRANKLIN INCOME \"A\" (HKD) INC","LU2361045086.USD":"WELLINGTON US QUALITY GROWTH \"A\" (USD) ACC","LU1974910355.USD":"Allianz Thematica Cl AMg DIS USD","LU0648001328.SGD":"Natixis Harris Associates US Equity RA SGD","LU1989771016.USD":"东方汇理环球老龄化投资基金 A2 Acc","BK4007":"制药","LU2125154935.USD":"ALLSPRING (LUX) WF GLOBAL EQUITY ENHANCED INCOME \"I\" (USD) INC","LU0058720904.USD":"联博国际健康护理基金A","SG9999001440.SGD":"United Global Dividend Equity Fund A SGD Dist","LU2468319806.SGD":"MANULIFE GF HEALTHCARE \"AA\" (SGDHDG) ACC","LU1989772840.SGD":"CPR Invest - Climate Action A2 Acc SGD-H","BK4121":"生命科学工具和服务","LU1093756325.SGD":"FTIF - Franklin K2 Alt Strat Fd A (acc) SGD-H1","LU1066051498.USD":"HSBC GIF GLOBAL EQUITY VOLATILITY FOCUSED \"AM2\" (USD) INC","LU0289739699.SGD":"AB INTERNATIONAL HEALTH CARE PORTFOLIO \"A\" (SGD) ACC","LU1989772923.USD":"CPR Invest - Climate Action A2 Acc USD-H","LU1037948897.HKD":"AB LOW VOLATILITY EQUITY PORTFOLIO \"AD\" (HKD) INC","LU1066053197.SGD":"HSBC GIF GLOBAL EQUITY VOLATILITY FOCUSED \"AM3\" (SGDHDG) INC","LU0965508806.USD":"AB LOW VOLATILITY EQUITY PORTFOLIO \"AD\" (USD) INC","LU1093756168.USD":"FRANKLIN K2 ALTERNATIVE STRATEGIES \"A\" (USD) ACC","LU2023250504.SGD":"Allianz Thematica Cl AMg DIS H2-SGD","LU0265550359.USD":"BGF SYSTEMATIC GLOBAL ENHANCED EQUITY YIELD \"A2\" (USD) ACC","IE00BJT1NW94.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"A2\" (SGDHDG) ACC","LU1934455277.USD":"AB SICAV I LOW VOLATILITY TOTAL RETURN EQUITY PORT \"AD\" (USD) INC"},"translate_title":"Inmena launches \"Billion Cell Atlas\" to accelerate artificial intelligence and drug discovery","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"AI":0.85,"ILMN":1.97},"content_text":"该图谱将以空前规模用于遗传靶点验证与 AI 模型训练 圣迭戈2026年1月14日 /美通社/ -- 2026年1月13日，因美纳公司（纳斯达克股票代码：ILMN）推出全球最大的、覆盖全基因组的遗传扰动数据集，旨在通过人工智能加速整个制药生态系统的药物发现进程。因美纳 \"十亿细胞图谱\"（Illumina Billion Cell Atlas）是其在三年内构建\"五十亿细胞图谱\"计划的首批成果，将成为迄今为止最为全面的人类疾病生物学图谱。 在与阿斯利康、美国默克公司和礼来公司等作为发起参与方组成的联盟框架下，该图谱已开始针对一组经甄选的细胞系开展构建工作，以推动药物靶点验证、大规模训练先进AI模型，并推进此前难以触及的基础疾病机制研究。 \"我们相信，细胞图谱是推动AI在药物发现领域实现显著规模化的关键进展。\" 因美纳首席执行官Jacob Thaysen表示。 \"我们正在构建一项业内领先的训练资源，用于新一代AI模型，服务于精准医疗与药物靶点识别，最终帮助绘制全球最具破坏性疾病背后的生物通路。\" 美国默克公司将利用该图谱加速其在药物发现管线中的精准医学研发策略。这些数据将用于训练美国默克公司自研的AI/ML基础模型并构建虚拟细胞模型，旨在提升对疾病适应症的预测能力。 \"通过利用先进的患者基因组数据集，美国默克公司的科学家正在构建并运用基于真实生物学变异，而非仅仅依赖文献语料的AI模型，并将这些洞察转化为能够真正惠及患者的全新靶点与精准生物标志物。\" 美国默克公司数据、人工智能与基因组科学副总裁兼负责人Iya Khalil表示，\"通过与因美纳的紧密合作，我们正在建立一座可扩展的桥梁，将基因组洞察转化为治疗影响，加速从发现到临床的路径，并以前所未有的信心与速度深化我们对复杂疾病生物学的理解。\" 人工智能与人类基因组学形塑生物医药发现的新前沿 该图谱将记录在超过200种疾病相关细胞系中，10亿个细胞个体对通过CRISPR引入的遗传改变的响应。这些细胞系因与疾病的相关性而被选取，其中许多疾病长期以来难以解码，包括免疫系统疾病和癌症，以及心脏代谢、神经系统和罕见遗传性疾病。CRISPR技术使研究人员能够在遍布全身的关键细胞类型中，快速研究对全部20,000个基因进行激活或抑制所产生的效应。 该图谱将帮助用户表征药物与疾病的作用机制，探索潜在的新适应症，并基于人类遗传学验证候选靶点。 \"将遗传信息转化为对疾病机制的清晰理解，并最终转化为药物，这仍然是研发领域的核心挑战，\"阿斯利康基因组研究中心副总裁Slavé Petrovski表示。\"通过揭示特定遗传扰动在人体细胞中如何发挥作用，我们能够把遗传信号转化为可直接研究的生物学机制，从而为药物开发决策带来更清晰的依据。\" \"新一代由AI驱动的药物发现将以前所未有规模的生物学数据为依托，\"礼来公司心脏代谢研究事业部集团副总裁Ruth Gimeno表示。\"覆盖多种细胞类型的综合性数据集，为产生关于人类疾病的有意义洞察提供了关键基础。\" BioInsight 团队如何构建因美纳首个数据产品  因美纳推出“十亿细胞图谱”，加速人工智能与药物发现  \"十亿细胞图谱\"是因美纳新业务部门BioInsight推出的首个数据产品。如此规模依托Illumina Single Cell 3' RNA prep产品的强大能力，单次实验可捕获数百万个单细胞。该图谱将以一年内20 PB的速率产出单细胞转录组数据。为处理如此海量的数据，单细胞RNA测序数据将采用具备硬件加速的因美纳DRAGEN分析流程进行处理，随后托管在Illumina Connected Analytics云平台上开展可扩展分析。 因美纳新成立的BioInsight业务部门旨在为制药领域的新一代药物发现与AI应用提供基础性技术与数据集。通过推出因美纳\"十亿细胞图谱\"，并开发面向特定疾病的综合基因扰动数据集，结合先进的AI算法，因美纳正在推动新一代细胞建模的进展。 因美纳正与其合作伙伴携手，不断扩展\"数十亿规模细胞图谱\"。此次\"十亿细胞图谱\"建立在因美纳于2025年2月宣布的合作倡议之上，其最终目标是创建一个\"五十亿单细胞图谱\"。 因美纳首席执行官Jacob Thaysen于2026年1月13日在第44届摩根大通医疗健康年会上发表演讲。网络直播可通过investor.illumina.com获取。关于 因美纳\"十亿细胞图谱\"和其他多组学项目的更多信息，请访问该链接。 前瞻性声明 本新闻稿可能包含涉及风险和不确定性的前瞻性声明。使我们的业务可能受到影响并导致实际结果与任何前瞻性声明存在实质性差异的重要因素包括但不限于： (i) 在研究、开发和推出新技术（包括未来的数十亿规模细胞图谱）过程中所固有的挑战； (ii) 我们及合作伙伴在部署新产品、服务与应用方面的能力，以及扩大与基因组学相关产品与服务市场的能力； 以及 (iii) 与多方合作相关的挑战，包括我们对这些合作伙伴表现的依赖；以及我们向美国证券交易委员会提交的文件（包括我们最近提交的10‑K表和10‑Q表）或在公开电话会议中披露的信息（该等电话会议的日期和时间将提前公布）中详述的其他因素。我们没有义务，也不打算更新这些前瞻性声明，审查或确认分析师的预期，或就本季度进展提供中期报告或更新。 关于因美纳 因美纳公司致力于推动和激发基因组学的发展而不断改善人类健康。专注创新使我们成为全球基因测序和芯片技术的领导者，并为全球范围的科研、临床和应用市场客户提供专业服务。我们的产品广泛应用于生命科学、肿瘤学、生殖保健、农业及其他新兴领域。欲了解更多信息，请访问或关注因美纳微信公众号。","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.42.0","shortVersion":"4.42.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2603664987","isCrawlerRequest":true}